Investment Thesis: NKE (Nike) — Dip-Buy
Date: 2026-04-01 Strategy: dip-buy News Category: guidance_cut (Q3 beat but weak China/Q4 outlook) Dip Score: 72.5
Thesis Summary
Buy Nike after -14.3% single-day earnings reaction. Q3 EPS beat estimates, NA sales grew 3%, but China sales -10% and Q4 guidance calls for 20% China decline crushed sentiment. At $45.27 (new 52-week low, -43% from high), the selloff prices in worst case. 4 of 6 analysts maintain BUY with $55-75 targets. First non-tech position — reduces portfolio correlation per Sage’s recommendation.
Agent Consensus
| Agent | Signal | Key Finding |
|---|---|---|
| Iris (News) | Bearish ST / Mixed MT | EPS beat but China guidance terrible. BofA downgraded. 4 BUYs remain. |
| Grace (Fundamentals) | Bullish | Brand moat intact. Turnaround under new CEO < 1 year old. At $45, a lot of bad news priced in. |
| Atlas (Backtest) | Marginal | 5 prior 10%+ drops: 60% WR, +9.13% avg at 30d. But earnings-driven drops are 50/50. |
| Victor (Risk) | Elevated | China real risk. Non-correlated to portfolio (positive). Stop at $40. |
| Diana (Decision) | BUY | Entry $45.27, target $55 (+21.5%), R/R 1.85:1 |
What Invalidates This Thesis
- Q4 China sales decline exceeds 20% guidance (worse than expected)
- NA sales growth reverses (turnaround stalls in home market)
- Brand relevance erodes (consumer shifts to On, Hoka, New Balance permanently)
Position
| Field | Value |
|---|---|
| Action | BUY |
| Entry | $45.27 |
| Shares | 44 |
| Position Size | $1,992 (9.4%) |
| Stop-Loss | $40.00 (-11.6%) |
| Target | $55.00 (+21.5%) |
| R/R | 1.85:1 |
| Time Horizon | 60-90 days |
| Risk Rating | Elevated |
First non-tech position. Reduces portfolio tech concentration from 37% and adds consumer discretionary diversification.